1887

Journal of General Virology header logo

Volume 105, Issue 1

Cyclooxygenase-2/prostaglandin E2 pathway regulates infectious bronchitis virus replication in avian macrophages Open Access

Abstract

Infectious bronchitis virus (IBV) is a significant respiratory pathogen that affects chickens worldwide. As an avian coronavirus, IBV leads to productive infection in chicken macrophages. However, the effects of IBV infection in macrophages on cyclooxygenase-2 (COX-2) expression are still to be elucidated. Therefore, we investigated the role of IBV infection on the production of COX-2, an enzyme involved in the synthesis of prostaglandin E2 (PGE2) in chicken macrophages. The chicken macrophage cells were infected with two IBV strains, and the cells and culture supernatants were harvested at predetermined time points to measure intracellular and extracellular IBV infection. IBV infection was quantified as has been the COX-2 and PGE2 productions. We found that IBV infection enhances COX-2 production at both mRNA and protein levels in chicken macrophages. When a selective COX-2 antagonist was used to reduce the COX-2 expression in macrophages, we observed that IBV replication decreased. When IBV-infected macrophages were treated with PGE2 receptor (EP2 and EP4) inhibitors, IBV replication was reduced. Upon utilizing a selective COX-2 antagonist to diminish PGE2 expression in macrophages, a discernible decrease in IBV replication was observed. Treatment of IBV-infected macrophages with a PGE2 receptor (EP2) inhibitor resulted in a reduction in IBV replication, whereas the introduction of exogenous PGE2 heightened viral replication. Additionally, pretreatment with a Janus-kinase two antagonist attenuated the inhibitory effect of recombinant chicken interferon (IFN)-γ on viral replication. The evaluation of immune mediators, such as inducible nitric oxide (NO) synthase (iNOS), NO, and interleukin (IL)−6, revealed enhanced expression following IBV infection of macrophages. In response to the inhibition of COX-2 and PGE2 receptors, we observed a reduction in the expressions of iNOS and IL-6 in macrophages, correlating with reduced IBV infection. Overall, IBV infection increased COX-2 and PGE2 production in addition to iNOS, NO, and IL-6 expression in chicken macrophages in a time-dependent manner. Inhibition of the COX-2/PGE2 pathway may lead to increased macrophage defence mechanisms against IBV infection, resulting in a reduction in viral replication and iNOS and IL-6 expressions. Understanding the molecular mechanisms underlying these processes may shed light on potential antiviral targets for controlling IBV infection.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): chicken macrophage , cyclooxygenase-2 inhibitor , infectious bronchitis virus , janus-kinase inhibitor and prostaglandin receptor antagonist
Funding
This study was supported by the:
  • Ministry of Higher Education and Scientific Research of the Arab Republic of Egypt (Award N/A)
    • Principle Award Recipient: MotamedElsayed Mahmoud
  • Natural Sciences and Engineering Research Council of Canada (Award RGPIN-2023-03364)
    • Principle Award Recipient: MohammadFaizal Abdul-Careem
© 2024 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001949
2024-01-08
2024-05-04
Loading full text...

Full text loading...

/deliver/fulltext/jgv/105/1/jgv001949.html?itemId=/content/journal/jgv/10.1099/jgv.0.001949&mimeType=html&fmt=ahah

References

  1. Ignjatovic J, Ashton DF, Reece R, Scott P, Hooper P. Pathogenicity of Australian strains of avian infectious bronchitis virus. J Comp Pathol 2002; 126:115–123 [View Article] [PubMed]
     [Google Scholar]
  2. Cavanagh D. Coronavirus avian infectious bronchitis virus. Vet Res 2007; 38:281–297 [View Article] [PubMed]
     [Google Scholar]
  3. Legnardi M, Tucciarone CM, Franzo G, Cecchinato M. Infectious bronchitis virus evolution, diagnosis and control. Vet Sci 2020; 7:79 [View Article] [PubMed]
     [Google Scholar]
  4. Thor SW, Hilt DA, Kissinger JC, Paterson AH, Jackwood MW. Recombination in avian gamma-coronavirus infectious bronchitis virus. Viruses 2011; 3:1777–1799 [View Article] [PubMed]
     [Google Scholar]
  5. Jackwood MW, Jordan BJ. Molecular evolution of infectious bronchitis virus and the emergence of variant viruses circulating in the United States. Avian Dis 2021; 65:631–636 [View Article] [PubMed]
     [Google Scholar]
  6. Rodrigues CMC, Plotkin SA. Impact of vaccines; health, economic and social perspectives. Front Microbiol 2020; 11:1526 [View Article] [PubMed]
     [Google Scholar]
  7. Bhuiyan MSA, Amin Z, Bakar AMSA, Saallah S, Yusuf NHM et al. Factor influences for diagnosis and vaccination of avian infectious bronchitis virus (Gammacoronavirus) in chickens. Vet Sci 2021; 8:47 [View Article] [PubMed]
     [Google Scholar]
  8. Winterfield RW, Hitchner SB. Etiology of an infectious nephritis-nephrosis syndrome of chickens. Am J Vet Res 1962; 23:1273–1279 [PubMed]
     [Google Scholar]
  9. Reddy VRAP, Trus I, Desmarets LMB, Li Y, Theuns S et al. Productive replication of nephropathogenic infectious bronchitis virus in peripheral blood monocytic cells, a strategy for viral dissemination and kidney infection in chickens. Vet Res 2016; 47:70 [View Article] [PubMed]
     [Google Scholar]
  10. Amarasinghe A, Abdul-Cader MS, Nazir S, De Silva Senapathi U, van der Meer F et al. Infectious bronchitis corona virus establishes productive infection in avian macrophages interfering with selected antimicrobial functions. PLoS One 2017; 12:e0181801 [View Article] [PubMed]
     [Google Scholar]
  11. Nikitina E, Larionova I, Choinzonov E, Kzhyshkowska J. Monocytes and macrophages as viral targets and reservoirs. Int J Mol Sci 2018; 19:2821 [View Article] [PubMed]
     [Google Scholar]
  12. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11:723–737 [View Article] [PubMed]
     [Google Scholar]
  13. Hirayama D, Iida T, Nakase H. The phagocytic function of macrophage-enforcing innate immunity and tissue homeostasis. Int J Mol Sci 2017; 19:92 [View Article] [PubMed]
     [Google Scholar]
  14. Rasheed A, Rayner KJ. Macrophage responses to environmental stimuli during homeostasis and disease. Endocr Rev 2021; 42:407–435 [View Article] [PubMed]
     [Google Scholar]
  15. Diamond MS, Kanneganti TD. Innate immunity: the first line of defense against SARS-CoV-2. Nat Immunol 2022; 23:165–176 [View Article] [PubMed]
     [Google Scholar]
  16. Chandrasekharan NV, Simmons DL. The cyclooxygenases. Genome Biol 2004; 5:241 [View Article] [PubMed]
     [Google Scholar]
  17. Zarghi A, Arfaei S. Selective COX-2 inhibitors: a review of their structure-activity relationships. Iran J Pharm Res 2011; 10:655–683 [PubMed]
     [Google Scholar]
  18. Brock TG, McNish RW, Peters-Golden M. Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J Biol Chem 1999; 274:11660–11666 [View Article] [PubMed]
     [Google Scholar]
  19. Kaltschmidt B, Linker RA, Deng J, Kaltschmidt C. Cyclooxygenase-2 is a neuronal target gene of NF-kappaB. BMC Mol Biol 2002; 3:16 [View Article] [PubMed]
     [Google Scholar]
  20. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38:97–120 [View Article] [PubMed]
     [Google Scholar]
  21. Sander WJ, O’Neill HG, Pohl CH. Prostaglandin E2 as a modulator of viral infections. Front Physiol 2017; 8:89 [View Article]
     [Google Scholar]
  22. Kulesza A, Paczek L, Burdzinska A. The role of COX-2 and PGE2 in the regulation of immunomodulation and other functions of mesenchymal stromal cells. Biomedicines 2023; 11:445 [View Article] [PubMed]
     [Google Scholar]
  23. Steer SA, Corbett JA. The role and regulation of COX-2 during viral infection. Viral Immunol 2003; 16:447–460 [View Article] [PubMed]
     [Google Scholar]
  24. Scanes CG. Avian physiology: are birds simply feathered mammals?. Front Physiol 2020; 11:542466 [View Article] [PubMed]
     [Google Scholar]
  25. Kwok AHY, Wang Y, Wang CY, Leung FC. Molecular cloning and characterization of chicken prostaglandin E receptor subtypes 2 and 4 (EP2 and EP4). Gen Comp Endocrinol 2008; 157:99–106 [View Article] [PubMed]
     [Google Scholar]
  26. Kwok AHY, Wang Y, Leung FC. Molecular characterization of prostaglandin F receptor (FP) and E receptor subtype 3 (EP3) in chickens. Gen Comp Endocrinol 2012; 179:88–98 [View Article] [PubMed]
     [Google Scholar]
  27. Boodhoo N, Kamble N, Kaufer BB, Behboudi S. Replication of Marek’s disease virus is dependent on synthesis of de novo fatty acid and prostaglandin E2. J Virol 2019; 93:e00352–19 [View Article]
     [Google Scholar]
  28. Kamble N, Gurung A, Kaufer BB, Pathan AA, Behboudi S. Marek’s disease virus modulates T cell proliferation via activation of cyclooxygenase 2-dependent prostaglandin E2. Front Immunol 2021; 12:801781 [View Article] [PubMed]
     [Google Scholar]
  29. Najimudeen SM, Abd-Elsalam RM, Ranaweera HA, Isham IM, Hassan MSH et al. Replication of infectious bronchitis virus (IBV) Delmarva (DMV)/1639 variant in primary and secondary lymphoid organs leads to immunosuppression in chickens [published online ahead of print, 2023 Jul 28]. Virology 2023; 587:109852 [View Article] [PubMed]
     [Google Scholar]
  30. Elhamouly M, Terada T, Nii T, Isobe N, Yoshimura Y. Innate antiviral immune response against infectious bronchitis virus and involvement of prostaglandin E2 in the uterine mucosa of laying hens. Theriogenology 2018; 110:122–129 [View Article] [PubMed]
     [Google Scholar]
  31. Chen S, Cheng A, Wang M. Innate sensing of viruses by pattern recognition receptors in birds. Vet Res 2013; 44:82 [View Article] [PubMed]
     [Google Scholar]
  32. Kameka AM, Haddadi S, Kim DS, Cork SC, Abdul-Careem MF. Induction of innate immune response following infectious bronchitis corona virus infection in the respiratory tract of chickens. Virology 2014; 450–451:114–121 [View Article] [PubMed]
     [Google Scholar]
  33. Abdul-Cader MS, Amarasinghe A, Abdul-Careem MF. Activation of toll-like receptor signaling pathways leading to nitric oxide-mediated antiviral responses. Arch Virol 2016; 161:2075–2086 [View Article] [PubMed]
     [Google Scholar]
  34. Lester SN, Li K. Toll-like receptors in antiviral innate immunity. J Mol Biol 2014; 426:1246–1264 [View Article] [PubMed]
     [Google Scholar]
  35. Garren MR, Ashcraft M, Qian Y, Douglass M, Brisbois EJ et al. Nitric oxide and viral infection: Recent developments in antiviral therapies and platforms. Appl Mater Today 2021; 22:100887 [View Article]
     [Google Scholar]
  36. Asif M, Lowenthal JW, Ford ME, Schat KA, Kimpton WG et al. Interleukin-6 expression after infectious bronchitis virus infection in chickens. Viral Immunol 2007; 20:479–486 [View Article] [PubMed]
     [Google Scholar]
  37. Saura M, Zaragoza C, McMillan A, Quick RA, Hohenadl C et al. An antiviral mechanism of nitric oxide: inhibition of a viral protease. Immunity 1999; 10:21–28 [View Article] [PubMed]
     [Google Scholar]
  38. Okino CH, Mores MAZ, Trevisol IM, Coldebella A, Montassier HJ et al. Early immune responses and development of pathogenesis of avian infectious bronchitis viruses with different virulence profiles. PLoS One 2017; 12:e0172275 [View Article] [PubMed]
     [Google Scholar]
  39. Sodano F, Gazzano E, Fruttero R, Lazzarato L. NO in viral infections: role and development of antiviral therapies. Molecules 2022; 27:2337 [View Article] [PubMed]
     [Google Scholar]
  40. Velazquez-Salinas L, Verdugo-Rodriguez A, Rodriguez LL, Borca MV. The role of interleukin 6 during viral infections. Front Microbiol 2019; 10:1057 [View Article] [PubMed]
     [Google Scholar]
  41. Sun X, Wang Z, Shao C, Yu J, Liu H et al. Analysis of chicken macrophage functions and gene expressions following infectious bronchitis virus M41 infection. Vet Res 2021; 52:14 [View Article] [PubMed]
     [Google Scholar]
  42. Hassan MSH, Ojkic D, Coffin CS, Cork SC, van der Meer F et al. Delmarva (DMV/1639) Infectious Bronchitis Virus (IBV) variants isolated in Eastern Canada Show evidence of recombination. Viruses 2019; 11:1054 [View Article] [PubMed]
     [Google Scholar]
  43. Najimudeen SM, Hassan MSH, Goldsmith D, Ojkic D, Cork SC et al. Molecular characterization of 4/91 Infectious Bronchitis Virus leading to studies of pathogenesis and host responses in laying hens. Pathogens 2021; 10:624 [View Article] [PubMed]
     [Google Scholar]
  44. Qureshi MA, Miller L, Lillehoj HS, Ficken MD. Establishment and characterization of a chicken mononuclear cell line. Vet Immunol Immunopathol 1990; 26:237–250 [View Article] [PubMed]
     [Google Scholar]
  45. Mahmoud ME, Ui F, Salman D, Nishimura M, Nishikawa Y. Mechanisms of interferon-beta-induced inhibition of toxoplasma gondii growth in murine macrophages and embryonic fibroblasts: role of immunity-related GTPase M1. Cell Microbiol 2015; 17:1069–1083 [View Article] [PubMed]
     [Google Scholar]
  46. Amarasinghe A, Abdul-Cader MS, Almatrouk Z, van der Meer F, Cork SC et al. Induction of innate host responses characterized by production of interleukin (IL)-1β and recruitment of macrophages to the respiratory tract of chickens following infection with infectious bronchitis virus (IBV). Vet Microbiol 2018; 215:1–10 [View Article] [PubMed]
     [Google Scholar]
  47. Han X, Tian Y, Guan R, Gao W, Yang X et al. Infectious bronchitis virus infection induces apoptosis during replication in chicken macrophage HD11 cells. Viruses 2017; 9:198 [View Article] [PubMed]
     [Google Scholar]
  48. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res 2015; 8:105–118 [View Article] [PubMed]
     [Google Scholar]
  49. Kim J, Wu D, Hwang DJ, Miller DD, Dalton JT. The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J Pharmacol Exp Ther 2005; 315:230–239 [View Article] [PubMed]
     [Google Scholar]
  50. Escobar-Zarate D, Liu YP, Suksanpaisan L, Russell SJ, Peng KW. Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors. Cancer Gene Ther 2013; 20:582–589 [View Article]
     [Google Scholar]
  51. Castaño E, Bartrons R, Gil J. Inhibition of cyclooxygenase-2 decreases DNA synthesis induced by platelet-derived growth factor in Swiss 3T3 fibroblasts. J Pharmacol Exp Ther 2000; 293:509–513 [PubMed]
     [Google Scholar]
  52. Yang Q, Burkardt AC, Sunkara LT, Xiao K, Zhang G. Natural cyclooxygenase-2 inhibitors synergize with butyrate to augment chicken host defense peptide gene expression. Front Immunol 2022; 13:819222 [View Article] [PubMed]
     [Google Scholar]
  53. Levy G, Guglielmelli P, Langmuir P, Constantinescu SN. JAK inhibitors and COVID-19 [published correction appears in J Immunother cancer. 2023 Apr;11(4)]. J Immunother Cancer 2022; 10:e002838 [View Article]
     [Google Scholar]
  54. Jain NK, Tailang M, Jain HK, Chandrasekaran B, Sahoo BM et al. Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: a review. Front Pharmacol 2023; 14:1135145 [View Article] [PubMed]
     [Google Scholar]
  55. Alfajaro MM, Choi J-S, Kim D-S, Seo J-Y, Kim J-Y et al. Activation of COX-2/PGE2 promotes sapovirus replication via the inhibition of nitric oxide production. J Virol 2017; 91:e01656-16 [View Article] [PubMed]
     [Google Scholar]
  56. Coulombe F, Jaworska J, Verway M, Tzelepis F, Massoud A et al. Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages. Immunity 2014; 40:554–568 [View Article] [PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001949
Loading
Cyclooxygenase-2/prostaglandin E2 pathway regulates infectious bronchitis virus replication in avian macrophages
J. Gen. Virol. 105, 001949 (2024); https://doi.org/10.1099/jgv.0.001949
/content/journal/jgv/10.1099/jgv.0.001949
/content/journal/jgv/10.1099/jgv.0.001949
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error